ReviewCancers2022
Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Pooled it
- Biomaterials' Role in Improving Patient Care from Drug Testing and Delivery to Theragnostics and Regenerative Medicine.Journal of functional biomaterials · 2026Review
- Occurrence, Properties, Applications and Analytics of Cytosine and Its Derivatives.Molecules (Basel, Switzerland) · 2025Review
- Embracing cancer immunotherapy with manganese particles.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- Antibody-Drug Conjugates for Breast Cancer Treatment: Emerging Agents, Targets and Future Directions.International journal of molecular sciences · 2023Review
- The Future of Radioactive Medicine.Radiation research · 2023Review
- Nanomedicines Meet Disordered Proteins: A Shift from Traditional Materials and Concepts to Innovative Polymers.Journal of personalized medicine · 2022Article
- Emerging Trends in Immunotherapy for Cancer.Diseases (Basel, Switzerland) · 2022Review
- Review
- Nanoparticle-based immunotherapy of pancreatic cancer.Frontiers in molecular biosciences · 2022Review
- Emerging Advances in Nanomedicine for Targeted Cancer Photoimmunotherapy and Photo-Immunometabolic Therapy.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Malignant lymphomas represent the most common type of hematologic malignancies. The first clinically approved TDD modalities in lymphoma patients were anti-CD20 radioimmunoconjugates (RIT)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.